Home/Biosimilar Atlas/Teriparatide/Terrosa / Movymia

Terrosa / Movymia

Teriparatide biosimilar developed by Richter-Helm BioTec and Gedeon Richter, development code RGB-10. Reference product Forsteo (Forteo in the United States).

Brands by market: Terrosa and Movymia (EU) · Commercial partner or holder: Gedeon Richter (Terrosa); Stada (Movymia) · Company profile
FDANot listed
EMAJan 2017authorised
MHRALicenseddate not shown
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 2 of 7 markets
Connections
TeriparatidemoleculeRichter-Helm BioTec and Gedeon Richterdeveloper2 of 7markets0trials behind it3other products, same developer8rival developers in its markets

About Terrosa / Movymia

Terrosa and Movymia are the same teriparatide, developed by Richter-Helm with Gedeon Richter and approved in Europe in January 2017 as the first teriparatide biosimilars. Richter sells Terrosa and Stada sells Movymia. Because the United States treats teriparatide as a drug, neither has a US biosimilar counterpart.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union · Terrosa

European Medicines Agency and European CommissionApproved
Brand
Terrosa
Holder or applicant
Gedeon Richter Plc.
Pathway
Centralised (Article 10(4))
Approved
Jan 2017
Application or permission
EMEA/H/C/003916
Indications as licensed
Osteoporosis in postmenopausal women and men; glucocorticoid-induced osteoporosis
Presentations
see SmPC
Remarks
First EU teriparatide biosimilar.
Source
S017 (EMA) · checked Sep 2026
EMA

European Union · Movymia

European Medicines Agency and European CommissionApproved
Brand
Movymia
Holder or applicant
STADA Arzneimittel AG
Pathway
Centralised (Article 10(4))
Approved
Jan 2017
Application or permission
EMEA/H/C/004368
Indications as licensed
Osteoporosis in postmenopausal women and men; glucocorticoid-induced osteoporosis
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
MHRA

United Kingdom · Movymia

Medicines and Healthcare products Regulatory AgencyApproved
Brand
Movymia
Holder or applicant
Not shown in the MHRA substance list
Pathway
UK marketing authorisation (Great Britain and, for EU-converted licences, Northern Ireland)
Approved
not published
Presentations
20 micrograms/80 microlitres
Source
S023 (MHRA Products) · checked Sep 2026
MHRA

United Kingdom · Terrosa

Medicines and Healthcare products Regulatory AgencyApproved
Brand
Terrosa
Holder or applicant
Not shown in the MHRA substance list
Pathway
UK marketing authorisation (Great Britain and, for EU-converted licences, Northern Ireland)
Approved
not published
Presentations
20 micrograms/80 microlitres
Source
S023 (MHRA Products) · checked Sep 2026
PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Not listed by CDSCO.

EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Terrosa / Movymia holds an approval, these are the other teriparatide biosimilars approved in that market.

MarketRivalsDevelopers (product)
EMA4CinnaGen (Zandoriah), Intas Pharmaceuticals (Sondelbay / Intas teriparatide), Not stated in the EMA table (Livogiva), Strides Pharma (Kauliv)
MHRA6Dr. Reddy's Laboratories (Teriparatide Dr. Reddy's), Intas Pharmaceuticals (Sondelbay / Intas teriparatide), Not stated in the MHRA list (Teriparatide Ambio Pharma), Strides Pharma (Kauliv), Sun Pharmaceutical Industries (Teriparatide Sun), Teva (Teriparatide Teva)

Same developer, other molecules

Other biosimilars in the Atlas developed by Gedeon Richter: Enoby / Xtrenbo / Junod / Yaxwer, Tuyory, Usymro.

Chronology

Sources

All teriparatide biosimilars

Planning teriparatide biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.